Perrigo buys OTC products from GSK
June 3, 2015Sales and Marketing GSK, GlaxoSmithKline, Mylan, Perrigo, Teva, brett wells
In an all-cash move with no financial details disclosed Perrigo is buying a portfolio of leading over-the-counter products from GlaxoSmithKline. …
Clark Health Communications hires three
June 3, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Clark Health Communications
Clark Health Communications (CHC) has announced the hire of three new team members. The UK, London-based firm has recently welcomed …
NICE: people should be more involved in medical decisions
June 2, 2015Sales and Marketing NHS, NICE, medicines, optimisation
Around 15 million people in England now have at least one long-term condition, but figures suggest that as many as …
Bayer and Gilead expand in manufacturing
June 2, 2015Manufacturing and Production, Sales and Marketing Bayer, Gilead, brett wells, manufacturing
Both Bayer and Gilead are investing heavily into their manufacturing operations with expansion plans being laid down in Indonesia and …
NICE signs-off Roche’s Gazyvaro for leukaemia
June 2, 2015Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia
NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …
Mylan tells Teva to ‘stop playing games’ and make firm bid
June 2, 2015Manufacturing and Production, Sales and Marketing M&A, MA, Mylan, Teva, generics
Mylan has written another strongly-worded letter to Teva, this time accusing the Israeli firm of ‘playing games’ and violating US …
Amgen hires head of Europe from Roche
June 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Corinne Le Goff, Roche
Corinne Le Goff is joining Amgen to be its senior vice president and head of the European region for the …
NICE Lynparza rejection labelled ‘hard to understand’
June 2, 2015Sales and Marketing AstraZeneca, NICE, lynparza, olaparib
AstraZeneca has appealed to the government to put ‘urgent transitional measures’ in place to make sure patients can access innovative …
AstraZeneca lung drug shines on
June 1, 2015Sales and Marketing ASCO, AZD9291, AstraZeneca, MEDI4736, NSCLC, Tafinlar
AstraZeneca’s investigational drug AZD9291 is continuing to impress, with results announced at cancer conference ASCO building on its previous ‘unprecedented’ …
BMS immunotherapy combination impresses at ASCO
June 1, 2015Research and Development, Sales and Marketing ASCO, BMS, Yervoy, opdivo
Bristol-Myers Squibb has presented data showing that a combination of its immunotherapies Opdivo and Yervoy significantly increases survival in advanced …
Pfizer breast cancer drug delivers
June 1, 2015Sales and Marketing ASCO, AZ, Faslodex, Pfizer, breast cancer, brett wells
A Phase III study on Pfizer’s treatment Ibrance in combination with hormone therapy has revealed the drug more than doubled …
Former GSK Oncology president joins Kesios
June 1, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Paolo Paoletti, kesios
The Imperial Innovations Group has confirmed the appointment of Dr Paolo Paoletti to be the executive chairman of Kesios Therapeutics.Paoletti …
Searching for new biotech solutions
June 1, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 23andME, Emily Drabant Conley, google
For pharma, the elevator pitch for 23andMe is an intriguing prospect. It has the largest genetic database in the world, …
BMS’ Opdivo improves lung cancer survival
May 29, 2015Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo
A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …
NICE green-light for Novartis skin drug
May 29, 2015Sales and Marketing Cosentyx, IL-17, NICE, Novartis, Secukinumab
NICE has released positive draft guidance for three treatments, including the first in a new generation of psoriasis drugs. Novartis’ …
Lilly and AstraZeneca collaborate on cancer trials
May 29, 2015Research and Development AstraZeneca, Cancer, Eli Lilly, MedImmune, immuno-oncology, immunotherapy, lilly, oncology, phase I
AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …
Pfizer gets first approval for rare lung disease
May 29, 2015Sales and Marketing FDA, Pfizer, Rapamune, lung disease
Pfizer’s Rapamune will become the first drug available to treat the very rare lung disease lymphangioleiomyomatosis (LAM) after receiving approval …
Teva settles generic ‘pay-to-delay’ case for $1.2 billion
May 29, 2015Sales and Marketing Cephalon, FTC, Teva, modafinil, provigil
Teva Pharmaceuticals has agreed to a $1.2 billion settlement for paying generic drug makers to delay challenging the patent for …
Sanofi plays host to German chancellor Angela Merkel
May 29, 2015Manufacturing and Production, Medical Communications, Sales and Marketing France, Germany, Sanofi, angela, brett wells, merkel
German Chancellor Dr Angela Merkel met with Sanofi bosses in Frankfurt to discuss antibiotics and open a new manufacturing facility. …
Huntingdon and Harlan names corporate marketing VP
May 29, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Huntingdon and Harlan, joseph bedford
UK’s Huntingdon Life Sciences and Harlan Laboratories has appointed Dr Joseph Bedford to serve as corporate vice president of global …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
